Oral anticoagulants (OACs) are commonly used to reduce the risk of venous
thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the …

Purpose We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

Background There are conflicting data on outcomes in patients with atrial fibrillation treated
with non–vitamin K oral anticoagulants across varying body mass index (BMI). We …

Aim The anticoagulation effect of warfarin is usually evaluated by percentage of time in
therapeutic range (PTTR), which is negatively correlated with the risk of warfarin adverse …

Abstract Background The 2021 International Society on Thrombosis and
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …

Background The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are
not well investigated in the obese population, and fixed dosing could lead to under …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke,
heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both …

Non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) are
important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular …

Atriyal fibrilasyonu (AF) olan hastalarda tromboembolik olay riskini azaltmak için oral
antikoagülanların rolü çok önemlidir. Bu amaçla, yaygın olarak kullanılan antikoagülan ilaç …